Accéder au contenu
Merck

Percutaneous steroidal treatment in relapses of chronic tendinopathies: a pilot study.

International journal of immunopathology and pharmacology (2011-04-19)
V Salini, M Abate
RÉSUMÉ

Relapses are frequently observed in subjects with chronic tendinopathies. Corticosteroid injections are usually performed with positive results, but are uncomfortable for the patient and not free from side effects. The aim of this pilot study is to evaluate the short-term efficacy and tolerability of an occlusive Betamethasone Valerate medicated Plaster (BMVP). Fifteen subjects with relapses of chronic tendinopathies (clinical and ultrasound diagnosis) were enrolled, and treated according to RICE (Rest - Ice - Compression - Elevation) protocol. An BMVP plaster was also applied on the affected tendon. Clinical examination, at baseline and after 7, 14, 21 and 28 days, included pain (VAS at rest and during activities) and functional evaluation. Local side effects on the area and drop-outs were also recorded. Pain, both at rest and during activities, significantly decreased at 28 days (from 3.7 ± 2.7 to 1.1 ± 1.7 p < 0.01, and from 7.3 ± 1.7 to 3.3 ± 1.4 p < 0.0000, respectively). Moreover, the patients reported a significant improvement in the functional limitation. Five subjects dropped out of the study. No side effects were reported. The release of the steroid in pharmacologically-active concentrations over 12 - 24 hours and the good penetration of the drug in subcutaneous tissues explain the positive results. BMVP application may be considered a reliable first therapeutic approach in relapses of chronic tendinopathies.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Betamethasone 17-valerate
Betamethasone 17-valerate, European Pharmacopoeia (EP) Reference Standard
Betamethasone 17-valerate, European Pharmacopoeia (EP) Reference Standard
Supelco
Betamethasone 17-valerate, VETRANAL®, analytical standard